About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Myc
myelocytomatosis oncogene
MGI:97250
140 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Aicdatm1(cre)Mnz/Aicda+
Ightm3Mnz/Igh+
Myctm39Mnz/Myc+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:145691
spontaneous chromosome breakage J:145691
Aicdatm1(cre)Mnz/Aicda+
Ightm3Mnz/Igh+
Myctm37Mnz/Myc+
involves: 129P2/OlaHsd * C57BL/6 		abnormal B cell physiology J:145691
spontaneous chromosome breakage J:145691
Aicdatm1Hon/Aicdatm1Hon
Ightm3Mnz/Igh+
Myctm37Mnz/Myc+
involves: C57BL/6 * CBA 		induced chromosome breakage J:145691
ApcMin/Apc+
Myctm1Jlc/Myc+
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J 		abnormal digestive system physiology J:134087
abnormal hematopoietic system morphology/development J:134087
normal hematopoietic system phenotype J:134087
intestine polyps J:134087
normal mortality/aging J:134087
Atg5tm1.1Myok/Atg5tm1.1Myok
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N 		abnormal cell physiology J:205532
Atmtm1Awb/Atmtm1Awb
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * FVB/N * SJL 		increased tumor incidence J:120284
premature death J:120284
Atmintm1.1Jhh/Atmintm1.1Jhh
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri 		increased lymphoma incidence J:230105
Atmintm1.1Jhh/Atmintm1.1Jhh
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0
B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri 		decreased B cell number J:230105
decreased immature B cell number J:230105
decreased lymphoma incidence J:230105
increased B cell apoptosis J:230105
increased tumor latency J:230105
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
increased leukocyte cell number J:186117
increased T cell derived lymphoma incidence J:186117
premature death J:186117
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
increased leukocyte cell number J:186117
premature death J:186117
Bcl2l11tm2.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
increased leukocyte cell number J:186117
premature death J:186117
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
increased leukocyte cell number J:186117
premature death J:186117
Bcl2l11tm3.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
premature death J:186117
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
Tg(IghMyc)22Bri/0
involves: C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:186117
premature death J:186117
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL 		abnormal cell physiology J:117330
abnormal enzyme/coenzyme activity J:117330
decreased apoptosis J:117330
increased cell proliferation J:117330
increased lymphoma incidence J:117330
increased mammary adenocarcinoma incidence J:117330
Boktm1.1Ast/Boktm1.1Ast
Tg(IghMyc)22Bri/0
involves: BALB/cJ * C57BL * C57BL/6 * SJL 		increased lymphoma incidence J:203179
Cd79atm1(cre)Reth/Cd79a+
Dynll1tm1.1Jhh/Dynll1tm1.1Jhh
Tg(IghMyc)22Bri/0
B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri 		decreased immature B cell number J:230105
decreased lymphoma incidence J:230105
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Myc)141-3Led/?
involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1 		normal neoplasm J:123144
Cdkn1btm1Mlf/Cdkn1b+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N 		decreased body size J:73369
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N 		decreased body size J:73369
decreased T cell proliferation J:73369
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Myctm1Atp/Myctm1Atp
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N 		prenatal lethality, complete penetrance J:73369
Cdkn2atm1Cjs/Cdkn2a+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * FVB/N * SJL 		decreased tumor incidence J:120284
premature death J:120284
Cks1btm1Sir/Cks1b+
Tg(IghMyc)22Bri/?
involves: C57BL * C57BL/6 * SJL 		increased lymphoma incidence J:121564
premature death J:121564
Cks1btm1Sir/Cks1btm1Sir
Tg(IghMyc)22Bri/?
involves: C57BL * C57BL/6 * SJL 		decreased B cell proliferation J:121564
decreased leukocyte cell number J:121564
decreased lymphocyte cell number J:121564
decreased metastatic potential J:121564
decreased spleen weight J:121564
increased lymphoma incidence J:121564
premature death J:121564
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 		no abnormal phenotype detected J:157298
Crebbptm2Pkb/Crebbp+
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal tumor incidence J:103607
Cul9tm1.2Yxi/Cul9+
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL 		abnormal tumor pathology J:170976
increased B cell derived lymphoma incidence J:170976
increased lymphoma incidence J:170976
premature death J:170976
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL 		abnormal tumor pathology J:170976
increased B cell derived lymphoma incidence J:170976
increased lymphoma incidence J:170976
premature death J:170976
Del(15Rr316124-Rr313939)2Fsp/+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6 		decreased B cell number J:257739
decreased bone marrow cell number J:257739
decreased granulocyte number J:257739
normal hematopoietic system phenotype J:257739
increased megakaryocyte cell number J:257739
increased myeloid cell number in bone marrow J:257739
Dmtf1tm1Cjs/Dmtf1+
Tg(IghMyc)22Bri/0
involves: 129/Sv * C57BL * C57BL/6 * SJL 		decreased tumor latency J:72617
Dnmt1tm1(tetO-BCL2)Sjk/Dnmt1+
Tg(IghMyc)22Bri/0
Tg(MMTVtTA)1Mam/0
involves: 129S4/SvJae * C57BL/6 		enlarged spleen J:93549
increased B cell derived lymphoma incidence J:93549
increased leukemia incidence J:93549
lethargy J:93549
premature death J:93549
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL * SJL 		abnormal tumor susceptibility J:103607
Ep300tm3Pkb/Ep300+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL/6 		abnormal tumor incidence J:103607
Fbxw7tm1Kei/Fbxw7tm1Kei
Myctm2Fwa/Myctm2Fwa
Tg(Cd4-cre)1Cwi/?
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2 		normal immune system phenotype J:128523
Fnip1LPAB.1/Fnip1LPAB.1
Tg(IghMyc)22Bri/0
involves: C57BL * C57BL/6J * SJL 		increased B cell apoptosis J:187318
normal neoplasm J:187318
Gt(ROSA)26Sortm12(CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 		decreased spleen germinal center size J:188564
Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 		normal immune system phenotype J:188564
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
involves: C57BL/6 * CBA 		abnormal hepatocyte morphology J:34434
increased hepatocellular carcinoma incidence J:34434, J:101128
increased liver adenoma incidence J:34434
increased liver tumor incidence J:101128
increased liver weight J:34434
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
involves: C57BL/6J * CBA/J 		abnormal circadian behavior J:190478
abnormal eating behavior J:190478
decreased body weight J:190478
impaired coordination J:190478
postnatal growth retardation J:190478
slow postnatal weight gain J:190478
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1 		abnormal hepatocyte morphology J:34434
increased hepatocellular carcinoma incidence J:34434
increased hepatocyte apoptosis J:34434
increased hepatocyte karyomegaly J:34434
increased liver adenoma incidence J:34434
increased liver weight J:34434
multifocal hepatic necrosis J:34434
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
Tg(Alb-E2F1)8Sst/0
involves: C57BL/6 * CBA 		increased hepatocellular carcinoma incidence J:101128
increased liver tumor incidence J:101128
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1Tg(Alb1-Myc)166.8Sst
involves: C57BL/6 * CBA 		abnormal mastication J:102709
asymmetric snout J:102709
decreased body weight J:102709
limb grasping J:102709
malocclusion J:102709
periorbital fullness J:102709
short snout J:102709
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1Tg(Alb1-Myc)166.8Sst
involves: C57BL/6J * CBA/J 		abnormal circadian behavior J:190478
abnormal eating behavior J:190478
abnormal fear/anxiety-related behavior J:190478
abnormal gait J:190478
abnormal jaw morphology J:190478
abnormal nest building behavior J:190478
abnormal response to new environment J:190478
decreased body weight J:190478
decreased grip strength J:190478
decreased vertical activity J:190478
impaired coordination J:190478
increased anxiety-related response J:190478
increased circulating corticosterone level J:190478
increased grooming behavior J:190478
increased response to stress-induced hyperthermia J:190478
limb grasping J:190478
periorbital fullness J:190478
postnatal growth retardation J:190478
short snout J:190478
slow postnatal weight gain J:190478
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1 		increased hepatocellular carcinoma incidence J:4527
Hunktm1Lach/Hunk+
Tg(MMTV-Myc)#Led/0
involves: 129P2/OlaHsd * C57BL/6J * CD-1 		decreased metastatic potential J:153075
Hunktm1Lach/Hunktm1Lach
Tg(MMTV-Myc)#Led/0
involves: 129P2/OlaHsd * C57BL/6J * CD-1 		decreased metastatic potential J:153075
Ightm1(Myc)Janz/Igh+
involves: 129X1/SvJ * C57BL/6 		abnormal tumor morphology J:160845
enlarged lymph nodes J:96785
enlarged spleen J:96785
increased B cell apoptosis J:96785
increased B cell derived lymphoma incidence J:96785, J:160845
increased B cell proliferation J:96785
increased plasmacytoma incidence J:96785, J:160845
increased tumor incidence J:96785, J:160845
lymphoid hyperplasia J:96785
Ightm1(Myc)Janz/Igh+
Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
involves: 129S/Sv * C57BL/6 		enlarged liver J:150341
enlarged lymph nodes J:150341
enlarged spleen J:150341
increased B cell derived lymphoma incidence J:150341
increased lymphoma incidence J:150341
increased splenocyte proliferation J:150341
premature death J:150341
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)A5Wmk/0
involves: 129X1/SvJ * C57BL/6 * FVB/N 		abnormal tumor morphology J:160845
increased B cell derived lymphoma incidence J:160845
increased plasmacytoma incidence J:160845
increased tumor incidence J:160845
Ightm1(Myc)Janz/Igh+
Tg(Emu-FGFR3)D3Wmk/0
involves: 129X1/SvJ * C57BL/6 * FVB/N 		abnormal tumor morphology J:160845
increased B cell derived lymphoma incidence J:160845
increased plasmacytoma incidence J:160845
increased tumor incidence J:160845
Ighatm1(Myc)Janz/Igha+
involves: 129S1/Sv * C57BL/6 		increased B cell apoptosis J:90901
increased B cell derived lymphoma incidence J:90901
increased B cell proliferation J:90901
increased plasma cell number J:90901
Ighatm1(Myc)Janz/Igha+
Tg(Tnfsf13b)1Fma/0
involves: 129S1/Sv * C57BL/6 * DBA/2J 		enlarged spleen J:166158
increased B cell number J:166158
increased chronic lymphocytic leukemia incidence J:166158
increased lymphocyte cell number J:166158
increased mature B cell number J:166158
increased spleen white pulp amount J:166158
premature death J:166158
Ighatm1(Myc)Janz/Igha+
Tg(Igk-V21-Bax)1967Bvn/0
involves: 129S1/Sv * C57BL/6 * FVB/N 		abnormal B cell apoptosis J:90901
abnormal plasma cell morphology J:90901
decreased tumor-free survival time J:90901
enlarged spleen J:90901
increased IgG level J:90901
increased IgM level J:90901
increased leukemia incidence J:90901
increased plasma cell number J:90901
increased plasmacytoma incidence J:90901
Ighmtm1Cgn/Ighmtm1Cgn
Tg(IghMyc)22Bri/0
involves: 129S2/SvPas * C57BL * SJL 		increased lymphoma incidence J:187318
Il15tm1Imx/Il15+
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6 		decreased memory T cell number J:132730
Il15tm1Imx/Il15tm1Imx
Myctm1Atp/Myc+
involves: 129P2/OlaHsd * C57BL/6 		decreased memory T cell number J:132730
decreased NK cell number J:132730
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL 		abnormal B cell physiology J:125164
abnormal DNA repair J:125164
increased B cell derived lymphoma incidence J:125164
premature death J:125164
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129 * C57BL * C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:125164
premature death J:125164
Klrb1btm1.1Apma/Klrb1btm1.1Apma
Tg(IghMyc)22Bri/0
involves: BALB/c * C57BL * C57BL/6 * SJL 		decreased tumor latency J:222057
Klrk1tm1Dhr/Klrk1tm1Dhr
Tg(IghMyc)22Bri/?
involves: C57BL/6 * CD-1 		increased B cell derived lymphoma incidence J:134509
Lect2tm1Ymg/Lect2tm1Ymg
Tg(Pklr-Myc)73Ak/0
B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak 		increased hepatocellular carcinoma incidence J:184496
increased malignant tumor incidence J:184496
Lrfn2Tg(CD2-Myb/en)5Kmw/Lrfn2+
Tg(H2-K-Myc)1Brn/?
involves: C57BL/10 * CBA * FVB/N 		abnormal bone marrow cell morphology/development J:125805
abnormal common myeloid progenitor cell morphology J:125805
abnormal erythropoiesis J:125805
abnormal lymph node morphology J:125805
enlarged lymph nodes J:125805
enlarged spleen J:125805
extramedullary hematopoiesis J:125805
lymph node hemorrhage J:125805
lymph node necrosis J:125805
premature death J:125805
spleen hyperplasia J:125805
Mapk14tm1.1Dvb/Mapk14+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL 		decreased tumor incidence J:120284
premature death J:120284
Mdm2tm1.1Ypz/Mdm2+
Tg(IghMyc)22Bri/0
B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri 		premature death J:164200
Mdm2tm1.1Ypz/Mdm2tm1.1Ypz
Tg(IghMyc)22Bri/0
B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri 		enlarged liver J:164200
enlarged lymph nodes J:164200
enlarged Peyer's patches J:164200
enlarged thymus J:164200
increased lymphoma incidence J:164200
premature death J:164200
spleen hyperplasia J:164200
Mdm4tm1Glo/Mdm4+
Tg(IghMyc)22Bri/0
involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:123661
Mirc1tm2.1Aven/Mirc1+
Tg(IghMyc)22Bri/?
involves: 129S4/SvJae * C57BL/6 * SJL/J 		abnormal survival J:223213
Mirc1tm2.1Aven/Mirc1tm2.1Aven
Tg(IghMyc)22Bri/?
involves: 129S4/SvJae * C57BL/6 * SJL/J 		abnormal pre-B cell morphology J:223213
abnormal survival J:223213
increased B cell apoptosis J:223213
increased B cell derived lymphoma incidence J:223213
increased tumor latency J:223213
Myctm2Fwa/Myc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1 		decreased osteosarcoma incidence J:319454
increased tumor-free survival time J:319454
Myctm2Fwa/Myctm2Fwa
Gt(ROSA)26Sortm1Sor/?
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA 		abnormal coronal suture morphology J:121871
abnormal frontal bone morphology J:121871
abnormal malleus morphology J:121871
short nasal bone J:121871
small malleus J:121871
small malleus manubrium J:121871
Myctm2Fwa/Myctm2Fwa
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1 		premature death J:319454
Npm1tm1Ppp/Npm1+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * C57BL/6 * SJL 		abnormal tumor morphology J:101494
increased B cell derived lymphoma incidence J:101494
Pknox1tm1Ngc/Pknox1+
Tg(IghMyc)22Bri/0
involves: C57BL * SJL 		decreased B cell apoptosis J:192251
increased B cell derived lymphoma incidence J:192251
increased B cell proliferation J:192251
premature death J:192251
Plcg2tm1Jni/Plcg2tm1Jni
Tg(IghMyc)22Bri/0
involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL 		enlarged lymph nodes J:117023
increased B cell derived lymphoma incidence J:117023
increased lymphoma incidence J:117023
premature death J:117023
Ppm1dtm1Lad/Ppm1d+
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL 		decreased tumor incidence J:120284
premature death J:120284
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
involves: 129S7/SvEvBrd * C57BL * FVB/N * SJL 		decreased tumor incidence J:120284
premature death J:120284
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
Trp53tm1Brd/Trp53+
involves: 129 * C57BL * FVB/N * SJL 		increased tumor incidence J:120284
premature death J:120284
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl
Tg(IghMyc)22Bri/0
B6.Cg-Prdm11tm1.1Ahl Tg(IghMyc)22Bri 		increased B cell derived lymphoma incidence J:221379
Prps2tm1a(KOMP)Wtsi/Y
Tg(IghMyc)22Bri/0
involves: C57BL/6N * SJL 		abnormal B cell physiology J:214383
abnormal survival J:214383
normal hematopoietic system phenotype J:214383
increased B cell apoptosis J:214383
increased tumor latency J:214383
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
Tg(Pklr-Myc)73Ak/0
B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak 		increased hepatocellular carcinoma incidence J:184496
increased malignant tumor incidence J:184496
increased metastatic potential J:184496
Tg(ACTB-Eif4e)#Ppp/0
Tg(IghMyc)22Bri/0
involves: C57BL * SJL 		decreased B cell apoptosis J:89878
increased lymphoma incidence J:89878
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)42Lmb/0
involves: C57BL/6 * CBA * CD-1 		abnormal hepatocyte morphology J:34434
increased hepatocellular carcinoma incidence J:34434
increased hepatocyte apoptosis J:34434
increased hepatocyte karyomegaly J:34434
increased liver adenoma incidence J:34434
increased liver weight J:34434
multifocal hepatic necrosis J:34434
Tg(Alb1-Myc)#Sst/0
Tg(MtTGFA)Lmb/0
involves: C57BL/6 * CBA * CD-1 		decreased NK cell number J:176432
increased hepatocellular carcinoma incidence J:176432
increased NK T cell number J:176432
Tg(BCL2)22Wehi/0
Tg(IghMyc)22Bri/0
involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi 		abnormal B cell morphology J:69571
abnormal pre-B cell morphology J:69571
enlarged lymph nodes J:69571
enlarged spleen J:69571
enlarged thymus J:69571
increased B cell number J:69571
increased leukocyte cell number J:69571
increased lymphoma incidence J:69571
increased pre-B cell number J:69571
premature death J:69571
Tg(EmuSR-tTa)83Bop/0
Tg(IghMyc)22Bri/0
Tg(tetO-RNAi:Trp53)ASlowe/0
involves: C57BL * C57BL/6 * FVB/N * SJL 		decreased tumor-free survival time J:123006
enlarged spleen J:123006
hindlimb paralysis J:123006
increased lymphoma incidence J:123006
Tg(Igh-Abl1)40Sco/0
Tg(IghMyc)22Bri/0
involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi 		enlarged mesenteric lymph nodes J:78204
increased plasmacytoma incidence J:78204
Tg(IghMyc)22Bri/0
Tg(Igk-V21-Bax)1967Bvn/0
involves: C57BL/6 * FVB/N 		abnormal liver morphology J:89049
enlarged spleen J:89049
increased B cell derived lymphoma incidence J:89049
increased plasmacytoma incidence J:89049
increased transitional stage B cell number J:89049
premature death J:89049
Tg(IghMyc)22Bri/0
Tg(Lck/Emu-Eif4e)#Ppp/0
involves: C57BL * SJL 		increased lymphoma incidence J:89878
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL 		increased B cell derived lymphoma incidence J:125164
premature death J:125164
Tg(IghMyc)22Bri/0
Xiaptm1Hs/Xiaptm1Hs
B6.Cg-Xiaptm1Hs Tg(IghMyc)22Bri 		decreased B cell proliferation J:138979
decreased leukocyte cell number J:138979
increased B cell apoptosis J:138979
normal mortality/aging J:138979
Tg(IghMyc)186Brn/0
Rpl24Bst/Rpl24+
involves: C57BL/LiA * C57BLKS * CBA/BrA 		normal cellular phenotype J:142390
normal immune system phenotype J:142390
increased apoptosis J:142390
normal neoplasm J:142390
Tg(IghMyc)186Brn/0
Rpl38tm1Rugg/Rpl38+
involves: C57BL/LiA * CBA/BrA 		normal cellular phenotype J:142390
increased apoptosis J:142390
normal neoplasm J:142390
Tg(MMTV-Cdc37)1Stp/0
Tg(MMTV-Myc)141-3Led/0
involves: C57BL/6 * CD-1 * DBA/2 * FVB/N 		increased Leydig cell number J:62465
increased Leydig cell tumor incidence J:62465
increased lymphoma incidence J:62465
increased mammary adenocarcinoma incidence J:62465
increased mammary gland tumor incidence J:62465
increased salivary adenocarcinoma incidence J:62465
increased tumor incidence J:62465
Tg(MMTV-Myc)141-3Led/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Kras2)12Hev/0
involves: C57BL/6J * CD-1 * FVB/N 		increased mammary gland tumor incidence J:133578
Tg(WapMyc)212Bri/0
Tg(WapTgfa)215Bri/0
involves: C57BL/6 * SJL 		abnormal involution of the mammary gland J:56318
abnormal lactation J:56318
increased mammary gland tumor incidence J:56318
mammary gland hyperplasia J:56318
premature death J:56318
Trp53tm1.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL 		increased lymphoma incidence J:198482
premature death J:198482
Trp53tm1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL 		increased lymphoma incidence J:198482
premature death J:198482
Trp53tm2.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * SJL 		premature death J:282255
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Tg(IghMyc)22Bri/0
involves: C57BL * C57BL/6N * FVB/N * SJL 		decreased survivor rate J:239679
increased B cell derived lymphoma incidence J:239679
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory